Assessment of Circulating Tumor Cells (CTCs) in Low Tumor Volume Prostate Cancer Patients
B Furusato, A Ali, PO Ts'o, ZP Lum, S Srivastava, S Brassell, DG McLeod, IA Sesterhenn. Armed Forces Institute of Pathology, Washington, DC; Uniformed Services University of the Health Sciences, Bethesda, MD; Walter Reed Army Medical Center, Washington, DC; CCC Diagnostics, LLC., Baltimore, MD
Background: The objective of this study was to assess the incidence of circulating tumor cells (CTCs) in low tumor volume (less than 0.5 cc) prostate cancer patients after radical prostatectomy (RP).
Design: Between 2000 and 2004, blood samples were collected in order to assess the CTCs from 64 consecutive radical prostatectomy patients. The prostatectomy specimens were processed by whole mounting and close step sectioning at 2.2 mm intervals. Clinicopathologic data were obtained, including patient age, race, clinical stage, biopsy grade, preoperative PSA, prostatectomy data (specimen weight, tumor volume, grade, stage, and surgical margin status), and follow-up PSA data. These parameters were then compared with the CTCs status.
Results: Nine of 64 RP patients had low volume prostate cancer. Among these, 7 patients had detectable levels of CTCs. In 2 of the 7 patients with positive CTCs, PSA elevation was observed. These 2 cases had a Gleason score of 3+3 (well differentiated tumor), organconfined disease and negative surgical margin for tumors.
Conclusions: Isolation and detection of circulating epithelial cells is possible in low volume prostate cancer patients. In the setting of low volume prostate cancer, CTCs may be associated with measurable PSA levels. However, only a one time event of detecting CTCs did not predict PSA failure. The clinical significance of measuring CTCs has yet to be defined.
Category: Genitourinary (including renal tumors)
Tuesday, March 23, 2010 1:00 PM
Poster Session IV # 117, Tuesday Afternoon